Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Awarded Unites States Patent For p53 Genes and Proteins

Premium

Exelixis has been awarded US Patent No. 6,762,291, “Insect p53 tumor suppressor genes and proteins.”

Inventors listed on the patent are: Andrew Buchman; Darren Platt; Michael Ollman; Lynn Young; Madelyn Demsky; Kevin Keegan; Lori Friedman; Casey Kopczynski; Jeffrey Larson; and Stephanie Robertson.

According to its abstract, the patent describes a family of p53 tumor suppressor nucleic acid and protein isolated from several insect species. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or misexpression, the abstract states. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein, and can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene, the abstract states. The patent also describes nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.